Metabolic markers predict response to immunotherapy before lung cancer surgery
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether certain markers in your blood or tissue can predict how well immunotherapy works before surgery for early-stage lung cancer. It aims to find out who benefits most from this treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer (the most common type) that is at stage IB, II, or IIIA, meaning it has not spread widely and doctors plan to remove it with surgery.
- You are feeling well enough to be up and about (ECOG performance status 0 or 1).
- Your organs and bone marrow are working well, as shown by standard blood tests.
- You have not had any prior chemotherapy, radiation, or immunotherapy for your lung cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for blood markers that can predict how well certain lung cancer treatments work before surgery. By joining, you help find a simple blood test to guide personalized care.
This trial is for people with stage IIA to IIIB non-small cell lung cancer that can be removed by surgery. It tests if certain white blood cells (neutrophils) can help predict how well chemotherapy combined with immunotherapy works before surgery.
This trial tests whether a blood test (ctDNA) can help predict how well a combination of chemotherapy and immunotherapy (and sometimes radiation) works before surgery for non-small cell lung cancer. It aims to see if the blood test can detect small amounts of remaining cancer to guide further treatment.
This trial studies a comprehensive treatment approach for lung cancer that combines immunotherapy given before surgery with standard surgery. It aims to understand how well this approach works by analyzing your medical data and samples.
This trial studies whether giving different cancer medicines before (and sometimes after) surgery improves outcomes for people with early-stage, operable lung cancer that has certain tumor markers. It may help by trying to shrink or control the cancer early and lower the chance it comes back.
This trial tests whether giving chemotherapy plus immunotherapy before surgery helps people with a specific type of advanced lung cancer. It aims to see if this approach can shrink tumors and make surgery more effective.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.